OBJECTIVES: To compare the efficacy of the fixed combination Calcipotriol (Cal) plus betamethasone dipropionate (BDP) aerosol foam with that of other topical therapies using 75% reduction in Psoriasis Area and Severity Index (PASI75) and Investigator’s Global Assessment of Disease Severity (IGA) as treatment end-points in adult patients with plaque psoriasis. METHODS:  In accordance with PRISMA guidelines, we performed a systematic literature review using MEDLINE, Embase, BIOSIS and the Cochrane Library to identify randomised controlled trials on the efficacy of topical treatments for psoriasis (of any severity) in adults, published between 1999 and 2015. Key outcomes considered were PASI75 and IGA at 4 weeks. The risk of bias was assessed according to the Cochrane handbook to assess the robustness of the results. As recommended by NICE, the resulting data were used in a Bayesian network meta-analysis (NMA) and outputs were odds ratios. Statistical significance was considered at the 5% level. RESULTS: The systematic literature review identified 10,421 records, of which 2,376 duplicates were excluded prior to 1^st pass review, 7,935 and 104 records were excluded after 1^st and 2^ndpass respectively. The main reasons for exclusion were studies not limited to a single topical therapy or studies not conducted in patients with psoriasis vulgaris only. 45 studies were included for full review, of these 23 were suitable for the NMA. For PASI75, Cal/BDP aerosol foam was statistically significantly more efficacious than 6 out of 8 comparator treatments at 4 weeks. For IGA, the Cal/BDP aerosol foam was statistically more efficacious than 16 out of 18 comparator treatments at 4 weeks. In addition, Cal/BDP aerosol foam showed greater efficacy to any of the comparators; 67% and 60% for IGA and PASI75, respectively. CONCLUSIONS: In our analyses, Cal/BDP aerosol foam is significantly more efficacious than most other topical treatments for psoriasis.